Oral antiviral treatments for COVID-19: opportunities and challenges

被引：0
作者：
Laila Rahmah
Sunny O. Abarikwu
Amanuel Godana Arero
Mickael Essouma
Aliyu Tijani Jibril
Andrzej Fal
Robert Flisiak
Rangarirai Makuku
Leander Marquez
Kawthar Mohamed
Lamin Ndow
Dorota Zarębska-Michaluk
Nima Rezaei
Piotr Rzymski
机构：
[1] Tehran University of Medical Sciences,School of Medicine
[2] Universal Scientific Education and Research Network (USERN),Department of Biochemistry
[3] University of Port Harcourt,Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute
[4] Universal Scientific Education and Research Network (USERN),Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences
[5] Tehran University of Medical Sciences,Department of Community Nutrition, School of Nutritional Sciences and Dietetics
[6] Universal Scientific Education and Research Network (USERN),Nutritional and Health Team (NHT)
[7] University of Yaoundé I,Department of Population Health, Division of Public Health
[8] Universal Scientific Education and Research Network,Collegium Medicum, Warsaw Faculty of Medicine
[9] Tehran University of Medical Sciences,Integrated Science Association (ISA)
[10] Universal Scientific Education and Research Network (USERN),Department of Infectious Diseases and Hepatology
[11] Universal Scientific Education and Research Network (USERN),College of Social Sciences and Philosophy
[12] Wroclaw Medical University,Education and Research Network (USERN)
[13] Cardinal Stefan Wyszyński University,Department of Infectious Diseases
[14] Universal Scientific Education and Research Network (USERN),Research Center for Immunodeficiencies, Children’s Medical Center
[15] Medical University of Białystok,Department of Immunology, School of Medicine
[16] Universal Scientific Education and Research Network (USERN),Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA)
[17] University of the Philippines Diliman,Department of Environmental Medicine
[18] Universal Scientific,undefined
[19] Universal Scientific Education and Research Network (USERN),undefined
[20] National Health Laboratory Service,undefined
[21] Universal Scientific Education and Research Network (USERN),undefined
[22] Jan Kochanowski University,undefined
[23] Tehran University of Medical Sciences,undefined
[24] Tehran University of Medical Sciences,undefined
[25] Universal Scientific Education and Research Network (USERN),undefined
[26] Poznan University of Medical Sciences,undefined
来源：
Pharmacological Reports | 2022年 / 74卷
关键词：
SARS-CoV-2; Pandemic; Pharmaceutical treatment; Antivirals; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication and prevent disease progression to a more severe form. However, the timing of antiviral treatment plays a crucial role in this regard. Oral antiviral drugs provide an opportunity to manage SARS-CoV-2 infection without a need for hospital admission, easing the general burden that COVID-19 can have on the healthcare system. This review paper (i) presents the potential pharmaceutical antiviral targets, including various host-based targets and viral-based targets, (ii) characterizes the first-generation anti-SARS-CoV-2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19, (iv) discusses ethical issues in such clinical trials and (v) presents challenges associated with the use of oral antivirals in clinical practice. Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence with SARS-CoV-2 in a manner that prevents healthcare from being overwhelmed. It is pivotal to ensure equal and fair global access to the currently available oral antivirals and those authorized in the future.
引用
收藏
页码：1255 / 1278
页数：23
相关论文
共 779 条
  • [1] Cucinotta D(2020)WHO declares COVID-19 a pandemic Acta Biomed 91 157-160
  • [2] Vanelli M(2020)Disease and healthcare burden of COVID-19 in the United States Nat Med 26 1212-1217
  • [3] Miller IF(2020)Global socio-economic losses and environmental gains from the Coronavirus pandemic PLoS ONE 15 1657-315
  • [4] Becker AD(2020)Dietary choices and Habits during COVID-19 Lockdown: experience from Poland Nutrients 12 368504211019854-9
  • [5] Grenfell BT(2021)COVID-19 pandemic: A review of the global lockdown and its far-reaching effects Sci Prog 104 312-307
  • [6] Metcalf CJE(2022)The pandemic’s true death toll: millions more than official counts Nature 601 4-110
  • [7] Lenzen M(2020)When science goes viral: The research response during three months of the COVID-19 outbreak Biomed Pharmacother 129 295-3366
  • [8] Li M(2021)Bibliometric analysis of global scientific research on COVID-19 J Biosaf Biosecur. 3 103-629
  • [9] Malik A(2021)Repurposing drugs for the management of COVID-19 Expert Opin Ther Pat 31 3359-359
  • [10] Pomponi F(2021)Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study Pol Arch Intern Med. 131 2723-209
12345678910